The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trialJuan José Rodríguez‐Sevilla, Simona Colla, Kelly S. Chien et al.|Nature Communications|2024Cited by 18